Nausea affected approximately 50% of participants at the 6 mg dose, making it the most commonly reported side effect
These drugs are co-prescribed with metformin to lower blood sugar without causing hypoglycemia and reducing the risk of obesity
![louisiana semaglutide vomiting class action in semaglutide diarrhea attorney in kentucky Are there Other Gastrointestinal Concerns with Semaglutide? Ozempic Lawsuit [2026 Update]](https://www.lawsuit-information-center.com/files/2022/10/social-image-logo-og.png)
Risk factors that may influence the decision to pause treatment include: Being in the dose-escalation phase of GLP-1 therapy Experiencing active gastrointestinal symptoms (nausea, vomiting, bloating) Having known gastroparesis or other conditions affecting gastric emptying Taking concurrent medications that further delay gastric emptying (e.g., opioids) Undergoing procedures with higher aspiration risk (e.g., emergency surgery, airway surgery) If your anaesthetist or surgical team advises temporary cessation based on your individual risk assessment, the timing will depend on the specific medication: Daily injections (such as liraglutide): Typically paused 24 hours before surgery Weekly injections (such as semaglutide, dulaglutide): Often paused with the last dose given at least 7 days before surgery Oral semaglutide (Rybelsus): Usually paused 24 hours before surgery However, these timings may vary according to local NHS Trust protocols and individual clinical assessment
![louisiana semaglutide vomiting class action in semaglutide diarrhea attorney in kentucky Are there Other Gastrointestinal Concerns with Semaglutide? Ozempic Lawsuit [2026 Update]](https://www.laborlawcenter.com/media/catalog/product/cache/dd4850ad4231b6306bceadf38a0bbeed/k/e/kentucky_1.png)
Diabetes Obes Metab 27(2):806815 Simms-Williams N, Treves N, Yin H, Lu S, Yu O, Pradhan R et al (2024) Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population-based cohort study